Muscular Dystrophy Association Celebrates FDA Approval of Biogen’s Qalsody for…
<!-- Name:DistributionId Value:8825434 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Biogens
FDA advisors vote against effectiveness of Biogen’s ALS drug for rare and…
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesThe Food and Drug Administration's…
FDA advisors reject Biogen’s ALS drug for rare and aggressive form of the…
A pedestrian walks past Biogen Inc. headquarters in Cambridge, Massachusetts, U.S., on Monday, June 7, 2021.Adam Glanzman | Bloomberg | Getty ImagesThe Food and Drug Administration's…
FDA staff says Biogen’s ALS drug may have a ‘clinical benefit’ on a…
U.S. Food and Drug Administration staff on Monday said Biogen's investigational ALS drug may have a "clinical benefit" on a rare and aggressive form of the disease, despite failing a broader…
FDA will review Eisai’s and Biogen’s Alzheimer’s treatment Leqembi…
Andrew Brookes | Image Source | Getty ImagesThe Food and Drug Administration will make a decision on whether to fully approve Eisai's and Biogen's Alzheimer's treatment Leqembi by July 6,…
New Data at ECTRIMS 2022 Highlight Biogen’s Commitment to Advancing Individualized…
Final safety and efficacy results from the Phase 3 EVOLVE-MS-1 trial demonstrate decreases in disease activity and favorable tolerability for VUMERITY® (diroximel fumarate) consistent with…
Biogen’s Stock Pullback Offers a Second Chance
After slipping to its lowest level since 2013, Biogen Inc. (NASDAQ:BIIB) was all but forgotten by growth investors. That changed in dramatic fashion late last month when the…
The New England Journal of Medicine Publishes Second Manuscript Reporting Positive…
Part A results from the two-part Phase 2 LILAC study show litifilimab significantly reduced disease activity based on active joint count in people with systemic lupus erythematosus (SLE)…
Biogen’s C.E.O. will step down following disastrous launch of Alzheimer’s drug.
Biogen said on Tuesday that it will replace its chief executive and effectively give up on marketing a high-profile Alzheimer’s drug that has been a commercial failure since its…
The FDA approved a new drug to treat Alzheimer’s, but Medicare won’t…
Medicare finalized its decision to restrict its coverage of Aduhelm, Biogen’s new Alzheimer’s disease drug, on April 8, 2022.
The decision means only patients who have enrolled in…